Resources
Downloads
Stay Updated
Latest News
Invitation from Ambigen Biotech at MEDICA 2025
November 17, 2025
AmbiGen Blotech to Showcase at MEDICA 2025 Germany -Join Us!
Read More
AmbiGen Biotech to Showcase at CACLP 2025 Hangzhou - Join Us!
March 19, 2025
AmbiGen Biotech will exhibit at the 22nd China Association of Clinical Laboratory Practice Expo (CACLP 2025), China's premier event for in vitro diagnostics.
Read More
Join Ambigen Biotech at CACLP Annual Party
September 4, 2024
On December 3, 2021, the National Healthcare Security Administration announced that the First-in-Class oral anti-influenza drug Xofluza, jointly developed by Shionogi and Roche, was officially included in the medical insurance catalog.
Read More
Respiratory Series — Mycoplasma pneumoniae Natural Antigen
September 2, 2024
Mycoplasma pneumoniae (MP) is the smallest prokaryotic pathogenic microorganism between viruses and bacteria that can grow and reproduce on cell-free culture media.
Read More
High-Sensitivity Influenza Antibodies — Accelerating Home Testing Trend
August 28, 2024
The First-in-Class oral anti-influenza drug Xofluza, jointly developed by Shionogi and Roche, was officially included in the medical insurance catalog.
Read More